A New Treatment For Aggressive Breast Cancer

InnovationHealthcareA New Treatment For Aggressive Breast CancerByWilliam A. Haseltine,Contributor.Forbes contributors publish independent expert analyses and insights. William A. Haseltine, Ph.D., covers genomics and regenerative medicineFollow AuthorJun 11, 2026, 11:18am EDTMiddle aged woman dressed in pink showing strength and smiling in a park. Fight against breast cancer.gettyA new targeted cancer drug may offer a better first treatment option for one of the most aggressive forms of breast cancer. In a large international clinical trial, patients receiving the drug lived longer and went nearly twice as long before their cancer worsened compared with those receiving standard chemotherapy. The treatment also shrank tumors more often and produced longer-lasting responses.Triple-negative breast cancer accounts for roughly 10% to 20% of breast cancer cases. Unlike many other breast cancers, it lacks the common targets that make hormone therapies and other precision medicines effective. The disease often spreads quickly, returns early and can be especially difficult to treat once it reaches other parts of the body.For many patients, chemotherapy remains the main treatment option. Immune-based therapies have improved outcomes for some people, but most patients with advanced triple-negative breast cancer are not candidates for those drugs. As a result, there has been growing interest in treatments that can deliver powerful cancer medicines more precisely while avoiding some of the limitations of traditional chemotherapy.A Guided Delivery SystemThe new treatment belongs to a growing class of medicines called antibody-drug conjugates. These therapies combine a targeting antibody with a chemotherapy drug.The antibody acts like a delivery address. It recognizes a protein found in high amounts on many breast cancer cells and attaches to it. Once attached, the cancer cell pulls the drug inside and releases the chemotherapy directly where it is needed.MORE FOR YOUTraditional...